Shares of Revolution Medicines, Inc. (RVMD) surged 9.91% during Tuesday's intraday session, marking a significant upward move for the biotech stock.

The sharp rise is attributed to continued investor optimism surrounding the company's lead drug candidate, daraxonrasib. Recent late-stage clinical trial data showed the pill nearly doubled survival compared to chemotherapy for pancreatic cancer patients, with potential U.S. Food and Drug Administration approval anticipated later this year. This breakthrough positions Revolution Medicines as a key player in targeting RAS-mutated cancers, a area of high unmet medical need.

Additionally, the stock appears to be staging a technical recovery following a recent pullback. The decline was triggered by a large-scale secondary offering, but the stock has found support amid robust fundamental prospects. Analyst firm HC Wainwright maintains a Buy rating on the stock with a price target of $169, highlighting significant potential upside from current levels.